What’s the real issue in NVAF – stroke or bleeding?

Sponsored by Bayer Australia Ltd

Evidence suggests that overstated concerns about bleeding with non-vitamin K antagonist oral anticoagulants (NOACs) are leaving many patients with non-valvular atrial fibrillation (NVAF) with renal dysfunction under-anticoagulated and therefore at risk for stroke.1 To help put the risk of major bleeding associated with NOACs versus the risk of stroke due to NVAF into perspective, the limbic ...

Already a member?

Login to keep reading.

© 2021 the limbic